The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Flu (Influenza) Vaccine Market Research Report 2025
Synopsis
Influenza vaccines, also known as flu shots, are vaccines that protect against influenza. A new version of the vaccine is developed twice a year as the influenza virus rapidly changes. Most provide modest to high protection against influenza; however, each year this varies. Evidence in adults over 65 years old is poor. They decrease the number of missed days of work by a half day on average. Vaccinating children may protect those around them.
The global Flu (Influenza) Vaccine market was valued at US$ 5505 million in 2023 and is anticipated to reach US$ 7665.1 million by 2030, witnessing a CAGR of 5.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Flu (Influenza) Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Flu (Influenza) Vaccine.
Report Scope
The Flu (Influenza) Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Flu (Influenza) Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Flu (Influenza) Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Hualan Bio
CCBIO
Aleph Biomedical
SANOFI
Adimmune
ZYAK
SINOVAC
Changsheng Biological
SIOBP
GSK
Aimei Hissen
Tianyuan Bio-pharma(Novartis)
Simcere Vaxtec
Segment by Type
Split Influenza Vaccine
Pandemic Influenza Vaccine
Subunit Influenza Vaccine
Quadrivalent Influenza Vaccine
Segment by Application
For Children (6 months to 3 years)
For Adults and Children over 3 years
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Flu (Influenza) Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Flu (Influenza) Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Influenza vaccines, also known as flu shots, are vaccines that protect against influenza. A new version of the vaccine is developed twice a year as the influenza virus rapidly changes. Most provide modest to high protection against influenza; however, each year this varies. Evidence in adults over 65 years old is poor. They decrease the number of missed days of work by a half day on average. Vaccinating children may protect those around them.
The global Flu (Influenza) Vaccine market was valued at US$ 5505 million in 2023 and is anticipated to reach US$ 7665.1 million by 2030, witnessing a CAGR of 5.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Flu (Influenza) Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Flu (Influenza) Vaccine.
Report Scope
The Flu (Influenza) Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Flu (Influenza) Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Flu (Influenza) Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Hualan Bio
CCBIO
Aleph Biomedical
SANOFI
Adimmune
ZYAK
SINOVAC
Changsheng Biological
SIOBP
GSK
Aimei Hissen
Tianyuan Bio-pharma(Novartis)
Simcere Vaxtec
Segment by Type
Split Influenza Vaccine
Pandemic Influenza Vaccine
Subunit Influenza Vaccine
Quadrivalent Influenza Vaccine
Segment by Application
For Children (6 months to 3 years)
For Adults and Children over 3 years
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Flu (Influenza) Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Flu (Influenza) Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Flu (Influenza) Vaccine Market Overview
1.1 Product Overview and Scope of Flu (Influenza) Vaccine
1.2 Flu (Influenza) Vaccine Segment by Type
1.2.1 Global Flu (Influenza) Vaccine Market Value Comparison by Type (2024-2030)
1.2.2 Split Influenza Vaccine
1.2.3 Pandemic Influenza Vaccine
1.2.4 Subunit Influenza Vaccine
1.2.5 Quadrivalent Influenza Vaccine
1.3 Flu (Influenza) Vaccine Segment by Application
1.3.1 Global Flu (Influenza) Vaccine Market Value by Application: (2024-2030)
1.3.2 For Children (6 months to 3 years)
1.3.3 For Adults and Children over 3 years
1.4 Global Flu (Influenza) Vaccine Market Size Estimates and Forecasts
1.4.1 Global Flu (Influenza) Vaccine Revenue 2019-2030
1.4.2 Global Flu (Influenza) Vaccine Sales 2019-2030
1.4.3 Global Flu (Influenza) Vaccine Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Flu (Influenza) Vaccine Market Competition by Manufacturers
2.1 Global Flu (Influenza) Vaccine Sales Market Share by Manufacturers (2019-2024)
2.2 Global Flu (Influenza) Vaccine Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Flu (Influenza) Vaccine Average Price by Manufacturers (2019-2024)
2.4 Global Flu (Influenza) Vaccine Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Flu (Influenza) Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Flu (Influenza) Vaccine, Product Type & Application
2.7 Flu (Influenza) Vaccine Market Competitive Situation and Trends
2.7.1 Flu (Influenza) Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Flu (Influenza) Vaccine Players Market Share by Revenue
2.7.3 Global Flu (Influenza) Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Flu (Influenza) Vaccine Retrospective Market Scenario by Region
3.1 Global Flu (Influenza) Vaccine Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Flu (Influenza) Vaccine Global Flu (Influenza) Vaccine Sales by Region: 2019-2030
3.2.1 Global Flu (Influenza) Vaccine Sales by Region: 2019-2024
3.2.2 Global Flu (Influenza) Vaccine Sales by Region: 2025-2030
3.3 Global Flu (Influenza) Vaccine Global Flu (Influenza) Vaccine Revenue by Region: 2019-2030
3.3.1 Global Flu (Influenza) Vaccine Revenue by Region: 2019-2024
3.3.2 Global Flu (Influenza) Vaccine Revenue by Region: 2025-2030
3.4 North America Flu (Influenza) Vaccine Market Facts & Figures by Country
3.4.1 North America Flu (Influenza) Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Flu (Influenza) Vaccine Sales by Country (2019-2030)
3.4.3 North America Flu (Influenza) Vaccine Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Flu (Influenza) Vaccine Market Facts & Figures by Country
3.5.1 Europe Flu (Influenza) Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Flu (Influenza) Vaccine Sales by Country (2019-2030)
3.5.3 Europe Flu (Influenza) Vaccine Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Flu (Influenza) Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Flu (Influenza) Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Flu (Influenza) Vaccine Sales by Country (2019-2030)
3.6.3 Asia Pacific Flu (Influenza) Vaccine Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Flu (Influenza) Vaccine Market Facts & Figures by Country
3.7.1 Latin America Flu (Influenza) Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Flu (Influenza) Vaccine Sales by Country (2019-2030)
3.7.3 Latin America Flu (Influenza) Vaccine Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Flu (Influenza) Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Flu (Influenza) Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Flu (Influenza) Vaccine Sales by Country (2019-2030)
3.8.3 Middle East and Africa Flu (Influenza) Vaccine Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Flu (Influenza) Vaccine Sales by Type (2019-2030)
4.1.1 Global Flu (Influenza) Vaccine Sales by Type (2019-2024)
4.1.2 Global Flu (Influenza) Vaccine Sales by Type (2025-2030)
4.1.3 Global Flu (Influenza) Vaccine Sales Market Share by Type (2019-2030)
4.2 Global Flu (Influenza) Vaccine Revenue by Type (2019-2030)
4.2.1 Global Flu (Influenza) Vaccine Revenue by Type (2019-2024)
4.2.2 Global Flu (Influenza) Vaccine Revenue by Type (2025-2030)
4.2.3 Global Flu (Influenza) Vaccine Revenue Market Share by Type (2019-2030)
4.3 Global Flu (Influenza) Vaccine Price by Type (2019-2030)
5 Segment by Application
5.1 Global Flu (Influenza) Vaccine Sales by Application (2019-2030)
5.1.1 Global Flu (Influenza) Vaccine Sales by Application (2019-2024)
5.1.2 Global Flu (Influenza) Vaccine Sales by Application (2025-2030)
5.1.3 Global Flu (Influenza) Vaccine Sales Market Share by Application (2019-2030)
5.2 Global Flu (Influenza) Vaccine Revenue by Application (2019-2030)
5.2.1 Global Flu (Influenza) Vaccine Revenue by Application (2019-2024)
5.2.2 Global Flu (Influenza) Vaccine Revenue by Application (2025-2030)
5.2.3 Global Flu (Influenza) Vaccine Revenue Market Share by Application (2019-2030)
5.3 Global Flu (Influenza) Vaccine Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Hualan Bio
6.1.1 Hualan Bio Corporation Information
6.1.2 Hualan Bio Description and Business Overview
6.1.3 Hualan Bio Flu (Influenza) Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Hualan Bio Flu (Influenza) Vaccine Product Portfolio
6.1.5 Hualan Bio Recent Developments/Updates
6.2 CCBIO
6.2.1 CCBIO Corporation Information
6.2.2 CCBIO Description and Business Overview
6.2.3 CCBIO Flu (Influenza) Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 CCBIO Flu (Influenza) Vaccine Product Portfolio
6.2.5 CCBIO Recent Developments/Updates
6.3 Aleph Biomedical
6.3.1 Aleph Biomedical Corporation Information
6.3.2 Aleph Biomedical Description and Business Overview
6.3.3 Aleph Biomedical Flu (Influenza) Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Aleph Biomedical Flu (Influenza) Vaccine Product Portfolio
6.3.5 Aleph Biomedical Recent Developments/Updates
6.4 SANOFI
6.4.1 SANOFI Corporation Information
6.4.2 SANOFI Description and Business Overview
6.4.3 SANOFI Flu (Influenza) Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 SANOFI Flu (Influenza) Vaccine Product Portfolio
6.4.5 SANOFI Recent Developments/Updates
6.5 Adimmune
6.5.1 Adimmune Corporation Information
6.5.2 Adimmune Description and Business Overview
6.5.3 Adimmune Flu (Influenza) Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Adimmune Flu (Influenza) Vaccine Product Portfolio
6.5.5 Adimmune Recent Developments/Updates
6.6 ZYAK
6.6.1 ZYAK Corporation Information
6.6.2 ZYAK Description and Business Overview
6.6.3 ZYAK Flu (Influenza) Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.6.4 ZYAK Flu (Influenza) Vaccine Product Portfolio
6.6.5 ZYAK Recent Developments/Updates
6.7 SINOVAC
6.6.1 SINOVAC Corporation Information
6.6.2 SINOVAC Description and Business Overview
6.6.3 SINOVAC Flu (Influenza) Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 SINOVAC Flu (Influenza) Vaccine Product Portfolio
6.7.5 SINOVAC Recent Developments/Updates
6.8 Changsheng Biological
6.8.1 Changsheng Biological Corporation Information
6.8.2 Changsheng Biological Description and Business Overview
6.8.3 Changsheng Biological Flu (Influenza) Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Changsheng Biological Flu (Influenza) Vaccine Product Portfolio
6.8.5 Changsheng Biological Recent Developments/Updates
6.9 SIOBP
6.9.1 SIOBP Corporation Information
6.9.2 SIOBP Description and Business Overview
6.9.3 SIOBP Flu (Influenza) Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.9.4 SIOBP Flu (Influenza) Vaccine Product Portfolio
6.9.5 SIOBP Recent Developments/Updates
6.10 GSK
6.10.1 GSK Corporation Information
6.10.2 GSK Description and Business Overview
6.10.3 GSK Flu (Influenza) Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.10.4 GSK Flu (Influenza) Vaccine Product Portfolio
6.10.5 GSK Recent Developments/Updates
6.11 Aimei Hissen
6.11.1 Aimei Hissen Corporation Information
6.11.2 Aimei Hissen Flu (Influenza) Vaccine Description and Business Overview
6.11.3 Aimei Hissen Flu (Influenza) Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Aimei Hissen Flu (Influenza) Vaccine Product Portfolio
6.11.5 Aimei Hissen Recent Developments/Updates
6.12 Tianyuan Bio-pharma(Novartis)
6.12.1 Tianyuan Bio-pharma(Novartis) Corporation Information
6.12.2 Tianyuan Bio-pharma(Novartis) Flu (Influenza) Vaccine Description and Business Overview
6.12.3 Tianyuan Bio-pharma(Novartis) Flu (Influenza) Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Tianyuan Bio-pharma(Novartis) Flu (Influenza) Vaccine Product Portfolio
6.12.5 Tianyuan Bio-pharma(Novartis) Recent Developments/Updates
6.13 Simcere Vaxtec
6.13.1 Simcere Vaxtec Corporation Information
6.13.2 Simcere Vaxtec Flu (Influenza) Vaccine Description and Business Overview
6.13.3 Simcere Vaxtec Flu (Influenza) Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Simcere Vaxtec Flu (Influenza) Vaccine Product Portfolio
6.13.5 Simcere Vaxtec Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Flu (Influenza) Vaccine Industry Chain Analysis
7.2 Flu (Influenza) Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Flu (Influenza) Vaccine Production Mode & Process
7.4 Flu (Influenza) Vaccine Sales and Marketing
7.4.1 Flu (Influenza) Vaccine Sales Channels
7.4.2 Flu (Influenza) Vaccine Distributors
7.5 Flu (Influenza) Vaccine Customers
8 Flu (Influenza) Vaccine Market Dynamics
8.1 Flu (Influenza) Vaccine Industry Trends
8.2 Flu (Influenza) Vaccine Market Drivers
8.3 Flu (Influenza) Vaccine Market Challenges
8.4 Flu (Influenza) Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Flu (Influenza) Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Flu (Influenza) Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Flu (Influenza) Vaccine Market Competitive Situation by Manufacturers in 2023
Table 4. Global Flu (Influenza) Vaccine Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Flu (Influenza) Vaccine Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Flu (Influenza) Vaccine Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Flu (Influenza) Vaccine Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Flu (Influenza) Vaccine Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Flu (Influenza) Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Flu (Influenza) Vaccine, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Flu (Influenza) Vaccine, Product Type & Application
Table 12. Global Key Manufacturers of Flu (Influenza) Vaccine, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Flu (Influenza) Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Flu (Influenza) Vaccine as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Flu (Influenza) Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Flu (Influenza) Vaccine Sales by Region (2019-2024) & (K Units)
Table 18. Global Flu (Influenza) Vaccine Sales Market Share by Region (2019-2024)
Table 19. Global Flu (Influenza) Vaccine Sales by Region (2025-2030) & (K Units)
Table 20. Global Flu (Influenza) Vaccine Sales Market Share by Region (2025-2030)
Table 21. Global Flu (Influenza) Vaccine Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Flu (Influenza) Vaccine Revenue Market Share by Region (2019-2024)
Table 23. Global Flu (Influenza) Vaccine Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Flu (Influenza) Vaccine Revenue Market Share by Region (2025-2030)
Table 25. North America Flu (Influenza) Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Flu (Influenza) Vaccine Sales by Country (2019-2024) & (K Units)
Table 27. North America Flu (Influenza) Vaccine Sales by Country (2025-2030) & (K Units)
Table 28. North America Flu (Influenza) Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Flu (Influenza) Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Flu (Influenza) Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Flu (Influenza) Vaccine Sales by Country (2019-2024) & (K Units)
Table 32. Europe Flu (Influenza) Vaccine Sales by Country (2025-2030) & (K Units)
Table 33. Europe Flu (Influenza) Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Flu (Influenza) Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Flu (Influenza) Vaccine Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Flu (Influenza) Vaccine Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Flu (Influenza) Vaccine Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Flu (Influenza) Vaccine Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Flu (Influenza) Vaccine Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Flu (Influenza) Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Flu (Influenza) Vaccine Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Flu (Influenza) Vaccine Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Flu (Influenza) Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Flu (Influenza) Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Flu (Influenza) Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Flu (Influenza) Vaccine Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Flu (Influenza) Vaccine Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Flu (Influenza) Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Flu (Influenza) Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Flu (Influenza) Vaccine Sales (K Units) by Type (2019-2024)
Table 51. Global Flu (Influenza) Vaccine Sales (K Units) by Type (2025-2030)
Table 52. Global Flu (Influenza) Vaccine Sales Market Share by Type (2019-2024)
Table 53. Global Flu (Influenza) Vaccine Sales Market Share by Type (2025-2030)
Table 54. Global Flu (Influenza) Vaccine Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Flu (Influenza) Vaccine Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Flu (Influenza) Vaccine Revenue Market Share by Type (2019-2024)
Table 57. Global Flu (Influenza) Vaccine Revenue Market Share by Type (2025-2030)
Table 58. Global Flu (Influenza) Vaccine Price (US$/Unit) by Type (2019-2024)
Table 59. Global Flu (Influenza) Vaccine Price (US$/Unit) by Type (2025-2030)
Table 60. Global Flu (Influenza) Vaccine Sales (K Units) by Application (2019-2024)
Table 61. Global Flu (Influenza) Vaccine Sales (K Units) by Application (2025-2030)
Table 62. Global Flu (Influenza) Vaccine Sales Market Share by Application (2019-2024)
Table 63. Global Flu (Influenza) Vaccine Sales Market Share by Application (2025-2030)
Table 64. Global Flu (Influenza) Vaccine Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Flu (Influenza) Vaccine Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Flu (Influenza) Vaccine Revenue Market Share by Application (2019-2024)
Table 67. Global Flu (Influenza) Vaccine Revenue Market Share by Application (2025-2030)
Table 68. Global Flu (Influenza) Vaccine Price (US$/Unit) by Application (2019-2024)
Table 69. Global Flu (Influenza) Vaccine Price (US$/Unit) by Application (2025-2030)
Table 70. Hualan Bio Corporation Information
Table 71. Hualan Bio Description and Business Overview
Table 72. Hualan Bio Flu (Influenza) Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Hualan Bio Flu (Influenza) Vaccine Product
Table 74. Hualan Bio Recent Developments/Updates
Table 75. CCBIO Corporation Information
Table 76. CCBIO Description and Business Overview
Table 77. CCBIO Flu (Influenza) Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. CCBIO Flu (Influenza) Vaccine Product
Table 79. CCBIO Recent Developments/Updates
Table 80. Aleph Biomedical Corporation Information
Table 81. Aleph Biomedical Description and Business Overview
Table 82. Aleph Biomedical Flu (Influenza) Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Aleph Biomedical Flu (Influenza) Vaccine Product
Table 84. Aleph Biomedical Recent Developments/Updates
Table 85. SANOFI Corporation Information
Table 86. SANOFI Description and Business Overview
Table 87. SANOFI Flu (Influenza) Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. SANOFI Flu (Influenza) Vaccine Product
Table 89. SANOFI Recent Developments/Updates
Table 90. Adimmune Corporation Information
Table 91. Adimmune Description and Business Overview
Table 92. Adimmune Flu (Influenza) Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Adimmune Flu (Influenza) Vaccine Product
Table 94. Adimmune Recent Developments/Updates
Table 95. ZYAK Corporation Information
Table 96. ZYAK Description and Business Overview
Table 97. ZYAK Flu (Influenza) Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. ZYAK Flu (Influenza) Vaccine Product
Table 99. ZYAK Recent Developments/Updates
Table 100. SINOVAC Corporation Information
Table 101. SINOVAC Description and Business Overview
Table 102. SINOVAC Flu (Influenza) Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. SINOVAC Flu (Influenza) Vaccine Product
Table 104. SINOVAC Recent Developments/Updates
Table 105. Changsheng Biological Corporation Information
Table 106. Changsheng Biological Description and Business Overview
Table 107. Changsheng Biological Flu (Influenza) Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Changsheng Biological Flu (Influenza) Vaccine Product
Table 109. Changsheng Biological Recent Developments/Updates
Table 110. SIOBP Corporation Information
Table 111. SIOBP Description and Business Overview
Table 112. SIOBP Flu (Influenza) Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. SIOBP Flu (Influenza) Vaccine Product
Table 114. SIOBP Recent Developments/Updates
Table 115. GSK Corporation Information
Table 116. GSK Description and Business Overview
Table 117. GSK Flu (Influenza) Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. GSK Flu (Influenza) Vaccine Product
Table 119. GSK Recent Developments/Updates
Table 120. Aimei Hissen Corporation Information
Table 121. Aimei Hissen Description and Business Overview
Table 122. Aimei Hissen Flu (Influenza) Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. Aimei Hissen Flu (Influenza) Vaccine Product
Table 124. Aimei Hissen Recent Developments/Updates
Table 125. Tianyuan Bio-pharma(Novartis) Corporation Information
Table 126. Tianyuan Bio-pharma(Novartis) Description and Business Overview
Table 127. Tianyuan Bio-pharma(Novartis) Flu (Influenza) Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 128. Tianyuan Bio-pharma(Novartis) Flu (Influenza) Vaccine Product
Table 129. Tianyuan Bio-pharma(Novartis) Recent Developments/Updates
Table 130. Simcere Vaxtec Corporation Information
Table 131. Simcere Vaxtec Description and Business Overview
Table 132. Simcere Vaxtec Flu (Influenza) Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 133. Simcere Vaxtec Flu (Influenza) Vaccine Product
Table 134. Simcere Vaxtec Recent Developments/Updates
Table 135. Key Raw Materials Lists
Table 136. Raw Materials Key Suppliers Lists
Table 137. Flu (Influenza) Vaccine Distributors List
Table 138. Flu (Influenza) Vaccine Customers List
Table 139. Flu (Influenza) Vaccine Market Trends
Table 140. Flu (Influenza) Vaccine Market Drivers
Table 141. Flu (Influenza) Vaccine Market Challenges
Table 142. Flu (Influenza) Vaccine Market Restraints
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Flu (Influenza) Vaccine
Figure 2. Global Flu (Influenza) Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Flu (Influenza) Vaccine Market Share by Type in 2023 & 2030
Figure 4. Split Influenza Vaccine Product Picture
Figure 5. Pandemic Influenza Vaccine Product Picture
Figure 6. Subunit Influenza Vaccine Product Picture
Figure 7. Quadrivalent Influenza Vaccine Product Picture
Figure 8. Global Flu (Influenza) Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 9. Global Flu (Influenza) Vaccine Market Share by Application in 2023 & 2030
Figure 10. For Children (6 months to 3 years)
Figure 11. For Adults and Children over 3 years
Figure 12. Global Flu (Influenza) Vaccine Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Flu (Influenza) Vaccine Market Size (2019-2030) & (US$ Million)
Figure 14. Global Flu (Influenza) Vaccine Sales (2019-2030) & (K Units)
Figure 15. Global Flu (Influenza) Vaccine Average Price (US$/Unit) & (2019-2030)
Figure 16. Flu (Influenza) Vaccine Report Years Considered
Figure 17. Flu (Influenza) Vaccine Sales Share by Manufacturers in 2023
Figure 18. Global Flu (Influenza) Vaccine Revenue Share by Manufacturers in 2023
Figure 19. The Global 5 and 10 Largest Flu (Influenza) Vaccine Players: Market Share by Revenue in 2023
Figure 20. Flu (Influenza) Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 21. Global Flu (Influenza) Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 22. North America Flu (Influenza) Vaccine Sales Market Share by Country (2019-2030)
Figure 23. North America Flu (Influenza) Vaccine Revenue Market Share by Country (2019-2030)
Figure 24. United States Flu (Influenza) Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Canada Flu (Influenza) Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 26. Europe Flu (Influenza) Vaccine Sales Market Share by Country (2019-2030)
Figure 27. Europe Flu (Influenza) Vaccine Revenue Market Share by Country (2019-2030)
Figure 28. Germany Flu (Influenza) Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. France Flu (Influenza) Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. U.K. Flu (Influenza) Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Italy Flu (Influenza) Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Russia Flu (Influenza) Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Asia Pacific Flu (Influenza) Vaccine Sales Market Share by Region (2019-2030)
Figure 34. Asia Pacific Flu (Influenza) Vaccine Revenue Market Share by Region (2019-2030)
Figure 35. China Flu (Influenza) Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. Japan Flu (Influenza) Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. South Korea Flu (Influenza) Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. India Flu (Influenza) Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Australia Flu (Influenza) Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. China Taiwan Flu (Influenza) Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Indonesia Flu (Influenza) Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Thailand Flu (Influenza) Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Malaysia Flu (Influenza) Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Latin America Flu (Influenza) Vaccine Sales Market Share by Country (2019-2030)
Figure 45. Latin America Flu (Influenza) Vaccine Revenue Market Share by Country (2019-2030)
Figure 46. Mexico Flu (Influenza) Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Brazil Flu (Influenza) Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Argentina Flu (Influenza) Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Middle East & Africa Flu (Influenza) Vaccine Sales Market Share by Country (2019-2030)
Figure 50. Middle East & Africa Flu (Influenza) Vaccine Revenue Market Share by Country (2019-2030)
Figure 51. Turkey Flu (Influenza) Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Saudi Arabia Flu (Influenza) Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. UAE Flu (Influenza) Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. Global Sales Market Share of Flu (Influenza) Vaccine by Type (2019-2030)
Figure 55. Global Revenue Market Share of Flu (Influenza) Vaccine by Type (2019-2030)
Figure 56. Global Flu (Influenza) Vaccine Price (US$/Unit) by Type (2019-2030)
Figure 57. Global Sales Market Share of Flu (Influenza) Vaccine by Application (2019-2030)
Figure 58. Global Revenue Market Share of Flu (Influenza) Vaccine by Application (2019-2030)
Figure 59. Global Flu (Influenza) Vaccine Price (US$/Unit) by Application (2019-2030)
Figure 60. Flu (Influenza) Vaccine Value Chain
Figure 61. Flu (Influenza) Vaccine Production Process
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Distributors Profiles
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
